Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 9.4%

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 1,260,000 shares, a decrease of 9.4% from the August 15th total of 1,390,000 shares. Based on an average daily trading volume, of 522,800 shares, the short-interest ratio is presently 2.4 days.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $7.60 on Thursday. The company has a market capitalization of $304.42 million, a P/E ratio of -1.57 and a beta of 0.65. AngioDynamics has a 1 year low of $5.26 and a 1 year high of $8.25. The business’s 50 day simple moving average is $7.39 and its 200 day simple moving average is $6.48.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The firm had revenue of $71.00 million for the quarter, compared to the consensus estimate of $70.86 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The company’s revenue was down 22.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 EPS. On average, sell-side analysts anticipate that AngioDynamics will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANGO. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research note on Wednesday, July 17th. Canaccord Genuity Group lowered their target price on AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Wednesday, July 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

Institutional Investors Weigh In On AngioDynamics

Large investors have recently modified their holdings of the business. Quarry LP boosted its holdings in shares of AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 2,594 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of AngioDynamics during the 4th quarter valued at $69,000. Mackenzie Financial Corp acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at $80,000. RPO LLC acquired a new stake in shares of AngioDynamics during the 4th quarter valued at $83,000. Finally, AE Wealth Management LLC acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at $87,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.